Toro
Diamond Member
Of course it doesn’t.
But you knew that.
But you knew that.
Question Does adding ivermectin, an inexpensive and widely available antiparasitic drug, to the standard of care reduce the risk of severe disease in patients with COVID-19 and comorbidities?
Findings In this open-label randomized clinical trial of high-risk patients with COVID-19 in Malaysia, a 5-day course of oral ivermectin administered during the first week of illness did not reduce the risk of developing severe disease compared with standard of care alone.
Meaning The study findings do not support the use of ivermectin for patients with COVID-19.
Efficacy of Ivermectin on Disease Progression in Patients With COVID-19
This randomized clinical trial assesses the efficacy of ivermectin treatment in preventing progression to severe disease among high-risk patients with COVID-19 in Malaysia.
jamanetwork.com